Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Crit Care Med. 2012 Oct;40(10):2833-40. doi: 10.1097/CCM.0b013e31825b88ba.
Supplementation with tetrahydrobiopterin, a nitric oxide synthase cofactor, may reduce microvascular endothelial dysfunction in severe sepsis. We studied whether tetrahydrobiopterin administration exerts beneficial effects in an ovine septic shock model.
Randomized animal study.
University hospital animal research laboratory.
Fourteen adult female sheep.
Fecal peritonitis was induced, and the sheep were randomized to receive tetrahydrobiopterin (n=7), given intravenously as 20 mg/kg boluses at 4 and 12 hrs after sepsis induction, or placebo (n=7). All animals were fluid resuscitated. The experiment was continued until death or for a maximum of 30 hrs.
In addition to standard hemodynamic assessment, the sublingual microcirculation was evaluated using sidestream dark-field videomicroscopy. The first bolus of tetrahydrobiopterin blunted the increase in heart rate and cardiac index seen in the control group without affecting mean arterial pressure, and the second bolus of tetrahydrobiopterin prevented the decreases in cardiac index and mean arterial pressure. The reduction in mixed venous blood oxygen saturation and the increase in blood lactate seen in the control group were also delayed. Tetrahydrobiopterin significantly attenuated the deterioration in perfused small vessel proportion and density, microvascular flow index, and the increase in microvascular heterogeneity observed in the control group. Tetrahydrobiopterin was associated with better preserved lung compliance and PaO2/FIO2 ratio, which were associated with a lower lung wet/dry weight ratio at the end of the study. Median survival time was significantly prolonged in the tetrahydrobiopterin group (25.0 vs. 17.8 hrs, p<.01).
In this clinically relevant model of sepsis, tetrahydrobiopterin supplementation attenuated the impairment in sublingual microvascular perfusion and permeability, which was accompanied by better preserved gas exchange, renal flow and urine output, and prolonged survival.
补充四氢生物蝶呤,一种一氧化氮合酶辅助因子,可能减轻严重脓毒症的微血管内皮功能障碍。我们研究了四氢生物蝶呤给药是否对绵羊感染性休克模型有益。
随机动物研究。
大学医院动物研究实验室。
14 只成年雌性绵羊。
粪便性腹膜炎诱导,绵羊随机接受四氢生物蝶呤(n=7),分别于感染后 4 小时和 12 小时静脉给予 20mg/kg 推注,或安慰剂(n=7)。所有动物均进行液体复苏。实验持续至死亡或最长 30 小时。
除了标准血流动力学评估外,还使用侧流暗场视频显微镜评估舌下微循环。四氢生物蝶呤的第一个推注剂抑制了对照组心率和心指数的增加,而不影响平均动脉压,第二个推注剂防止了心指数和平均动脉压的降低。对照组混合静脉血氧饱和度降低和血乳酸增加也被延迟。四氢生物蝶呤还显著减轻了对照组观察到的灌注小血管比例和密度、微血管血流指数以及微血管异质性的恶化。四氢生物蝶呤与更好地保留肺顺应性和 PaO2/FIO2 比值相关,这与研究结束时更低的肺湿/干重比相关。四氢生物蝶呤组的中位生存时间明显延长(25.0 小时对 17.8 小时,p<.01)。
在这种具有临床相关性的脓毒症模型中,四氢生物蝶呤补充剂减轻了舌下微血管灌注和通透性的损害,同时更好地保留了气体交换、肾血流量和尿量,并延长了生存时间。